Cargando…

Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases

There have been previous studies, especially in Western countries and even in some areas in Asia, about extra-intestinal manifestations (EIMs) and its link with the outcome of inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and ulcerative colitis (UC). This link is crucial whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez Meza, Miguel Ricardo, Nakamura, Masanao, Yamamura, Takeshi, Maeda, Keiko, Sawada, Tsunaki, Ishikawa, Eri, Kakushima, Naomi, Furukawa, Kazuhiro, Iida, Tadashi, Mizutani, Yasuyuki, Ishikawa, Takuya, Ohno, Eizaburo, Honda, Takashi, Kawashima, Hiroki, Ishigami, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748329/
https://www.ncbi.nlm.nih.gov/pubmed/36544593
http://dx.doi.org/10.18999/nagjms.84.4.733
_version_ 1784849802040705024
author Rodríguez Meza, Miguel Ricardo
Nakamura, Masanao
Yamamura, Takeshi
Maeda, Keiko
Sawada, Tsunaki
Ishikawa, Eri
Kakushima, Naomi
Furukawa, Kazuhiro
Iida, Tadashi
Mizutani, Yasuyuki
Ishikawa, Takuya
Ohno, Eizaburo
Honda, Takashi
Kawashima, Hiroki
Ishigami, Masatoshi
author_facet Rodríguez Meza, Miguel Ricardo
Nakamura, Masanao
Yamamura, Takeshi
Maeda, Keiko
Sawada, Tsunaki
Ishikawa, Eri
Kakushima, Naomi
Furukawa, Kazuhiro
Iida, Tadashi
Mizutani, Yasuyuki
Ishikawa, Takuya
Ohno, Eizaburo
Honda, Takashi
Kawashima, Hiroki
Ishigami, Masatoshi
author_sort Rodríguez Meza, Miguel Ricardo
collection PubMed
description There have been previous studies, especially in Western countries and even in some areas in Asia, about extra-intestinal manifestations (EIMs) and its link with the outcome of inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and ulcerative colitis (UC). This link is crucial when discussing a patient’s prognosis and important when dealing with UC management. The aim of this study was to clarify the most common comorbidities associated with UC, emphasizing immunologic comorbidities in Japan. This study was a retrospective analysis performed at Nagoya University Hospital. The data collection started in March, 2019, and continued for two years. We retrieved the medical records of 105 patients with UC diagnosis, from which the data of 176 EIMs were extracted and analyzed. Results showed that EIMs with UC in the active phase accounted for 43.7% of total EIMs. Twenty-six patients with immune-mediated inflammatory disease frequently had an active phase (odds ratio [OR] 3.84, 99% CI, 1.44–10.27). Comorbidities showing an active manifestation of symptoms and UC in the active phase were significantly correlated in patients with immunological comorbidities, such as peripheral arthritis (r = 0.97, p < 0.01) and rheumatoid arthritis (RA) (r = 0.99, p < 0.01), as well as in patients with primary sclerosis cholangitis (PSC) (r = 0.98, p < 0.01). In conclusion, this analysis suggests the importance of having full comprehension of how immunological comorbidities affect the natural development of UC, which is of vital importance to prevent further UC complications and properly adjust the management of the disease.
format Online
Article
Text
id pubmed-9748329
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nagoya University
record_format MEDLINE/PubMed
spelling pubmed-97483292022-12-20 Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases Rodríguez Meza, Miguel Ricardo Nakamura, Masanao Yamamura, Takeshi Maeda, Keiko Sawada, Tsunaki Ishikawa, Eri Kakushima, Naomi Furukawa, Kazuhiro Iida, Tadashi Mizutani, Yasuyuki Ishikawa, Takuya Ohno, Eizaburo Honda, Takashi Kawashima, Hiroki Ishigami, Masatoshi Nagoya J Med Sci Original Paper There have been previous studies, especially in Western countries and even in some areas in Asia, about extra-intestinal manifestations (EIMs) and its link with the outcome of inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and ulcerative colitis (UC). This link is crucial when discussing a patient’s prognosis and important when dealing with UC management. The aim of this study was to clarify the most common comorbidities associated with UC, emphasizing immunologic comorbidities in Japan. This study was a retrospective analysis performed at Nagoya University Hospital. The data collection started in March, 2019, and continued for two years. We retrieved the medical records of 105 patients with UC diagnosis, from which the data of 176 EIMs were extracted and analyzed. Results showed that EIMs with UC in the active phase accounted for 43.7% of total EIMs. Twenty-six patients with immune-mediated inflammatory disease frequently had an active phase (odds ratio [OR] 3.84, 99% CI, 1.44–10.27). Comorbidities showing an active manifestation of symptoms and UC in the active phase were significantly correlated in patients with immunological comorbidities, such as peripheral arthritis (r = 0.97, p < 0.01) and rheumatoid arthritis (RA) (r = 0.99, p < 0.01), as well as in patients with primary sclerosis cholangitis (PSC) (r = 0.98, p < 0.01). In conclusion, this analysis suggests the importance of having full comprehension of how immunological comorbidities affect the natural development of UC, which is of vital importance to prevent further UC complications and properly adjust the management of the disease. Nagoya University 2022-11 /pmc/articles/PMC9748329/ /pubmed/36544593 http://dx.doi.org/10.18999/nagjms.84.4.733 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Original Paper
Rodríguez Meza, Miguel Ricardo
Nakamura, Masanao
Yamamura, Takeshi
Maeda, Keiko
Sawada, Tsunaki
Ishikawa, Eri
Kakushima, Naomi
Furukawa, Kazuhiro
Iida, Tadashi
Mizutani, Yasuyuki
Ishikawa, Takuya
Ohno, Eizaburo
Honda, Takashi
Kawashima, Hiroki
Ishigami, Masatoshi
Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
title Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
title_full Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
title_fullStr Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
title_full_unstemmed Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
title_short Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
title_sort analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748329/
https://www.ncbi.nlm.nih.gov/pubmed/36544593
http://dx.doi.org/10.18999/nagjms.84.4.733
work_keys_str_mv AT rodriguezmezamiguelricardo analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT nakamuramasanao analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT yamamuratakeshi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT maedakeiko analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT sawadatsunaki analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT ishikawaeri analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT kakushimanaomi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT furukawakazuhiro analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT iidatadashi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT mizutaniyasuyuki analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT ishikawatakuya analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT ohnoeizaburo analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT hondatakashi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT kawashimahiroki analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases
AT ishigamimasatoshi analysisofimmunologiccomorbiditiesinulcerativecolitispatientsatooltopreventexacerbationsinulcerativecolitiscases